UY34911A - Compuestos no esteroideos moduladores del receptor de andrógeno. - Google Patents

Compuestos no esteroideos moduladores del receptor de andrógeno.

Info

Publication number
UY34911A
UY34911A UY0001034911A UY34911A UY34911A UY 34911 A UY34911 A UY 34911A UY 0001034911 A UY0001034911 A UY 0001034911A UY 34911 A UY34911 A UY 34911A UY 34911 A UY34911 A UY 34911A
Authority
UY
Uruguay
Prior art keywords
androgen receptor
receptor modulator
modulator compounds
steroidal androgen
steroidal
Prior art date
Application number
UY0001034911A
Other languages
English (en)
Spanish (es)
Inventor
Philip Stewart Turnbull
Cadilla Rodolfo
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49117887&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY34911(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of UY34911A publication Critical patent/UY34911A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
UY0001034911A 2012-07-17 2013-07-15 Compuestos no esteroideos moduladores del receptor de andrógeno. UY34911A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261672455P 2012-07-17 2012-07-17
US201361748874P 2013-01-04 2013-01-04

Publications (1)

Publication Number Publication Date
UY34911A true UY34911A (es) 2014-02-28

Family

ID=49117887

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034911A UY34911A (es) 2012-07-17 2013-07-15 Compuestos no esteroideos moduladores del receptor de andrógeno.

Country Status (39)

Country Link
US (5) US8957104B2 (cg-RX-API-DMAC7.html)
EP (1) EP2875013B1 (cg-RX-API-DMAC7.html)
JP (1) JP6106746B2 (cg-RX-API-DMAC7.html)
KR (1) KR102127939B1 (cg-RX-API-DMAC7.html)
CN (1) CN104619693B (cg-RX-API-DMAC7.html)
AR (1) AR091770A1 (cg-RX-API-DMAC7.html)
AU (1) AU2013291721B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015000940B1 (cg-RX-API-DMAC7.html)
CA (1) CA2879104C (cg-RX-API-DMAC7.html)
CL (1) CL2015000119A1 (cg-RX-API-DMAC7.html)
CO (1) CO7240378A2 (cg-RX-API-DMAC7.html)
CR (1) CR20150008A (cg-RX-API-DMAC7.html)
CY (1) CY1120064T1 (cg-RX-API-DMAC7.html)
DK (1) DK2875013T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2015000004A (cg-RX-API-DMAC7.html)
EA (1) EA026371B8 (cg-RX-API-DMAC7.html)
ES (1) ES2657912T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20180061T1 (cg-RX-API-DMAC7.html)
HU (1) HUE036238T2 (cg-RX-API-DMAC7.html)
IL (1) IL236448A (cg-RX-API-DMAC7.html)
IN (1) IN2014KN02993A (cg-RX-API-DMAC7.html)
JO (1) JO3384B1 (cg-RX-API-DMAC7.html)
LT (1) LT2875013T (cg-RX-API-DMAC7.html)
ME (1) ME02996B (cg-RX-API-DMAC7.html)
MX (1) MX349943B (cg-RX-API-DMAC7.html)
MY (2) MY198512A (cg-RX-API-DMAC7.html)
NZ (1) NZ703129A (cg-RX-API-DMAC7.html)
PE (1) PE20150371A1 (cg-RX-API-DMAC7.html)
PH (1) PH12015500104A1 (cg-RX-API-DMAC7.html)
PL (1) PL2875013T3 (cg-RX-API-DMAC7.html)
PT (1) PT2875013T (cg-RX-API-DMAC7.html)
RS (1) RS56810B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201408493WA (cg-RX-API-DMAC7.html)
SI (1) SI2875013T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800115T1 (cg-RX-API-DMAC7.html)
TW (1) TWI574946B (cg-RX-API-DMAC7.html)
UY (1) UY34911A (cg-RX-API-DMAC7.html)
WO (1) WO2014013309A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201500096B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10155099B2 (en) 2009-09-21 2018-12-18 Cook Regentec Llc Method for infusing stem cells
BR112015000940B1 (pt) 2012-07-17 2022-05-17 Glaxosmithkline Intellectual Property (No. 2) Limited Composto, composição farmacêutica, e, uso de um composto
EP3097077A1 (en) * 2014-01-21 2016-11-30 Glaxosmithkline Intellectual Property (No. 2) Limited Crystalline forms of (r)-1 -(1-(methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)indoline-5-carbonitrile
CA2964371A1 (en) * 2014-10-16 2016-04-21 Gtx, Inc. Methods of treating urological disorders using sarms
CN105130872B (zh) * 2015-08-25 2018-01-30 江西师范大学 一种3位三氟甲基取代吲哚的制备方法
CN110437125B (zh) * 2019-09-06 2021-03-12 苏州旺山旺水生物医药有限公司 一种Tezacaftor中间体II的制备方法
US20220306609A1 (en) * 2021-03-23 2022-09-29 Nido Biosciences, Inc. Bicyclic compounds as androgen receptor modulators
CN115010574B (zh) * 2022-06-06 2024-01-05 爱斯特（成都）生物制药股份有限公司 1-溴-2-氯-4-氟-2碘苯的合成方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010041343A (ko) 1998-02-25 2001-05-15 브루스 엠. 에이센, 토마스 제이 데스로저 포스포리파제 효소의 억제제
EA005852B1 (ru) * 1998-06-19 2005-06-30 Пфайзер Продактс Инк. ПИРРОЛО[2,3-d]ПИРИМИДИНЫ
US6576265B1 (en) 1999-12-22 2003-06-10 Acell, Inc. Tissue regenerative composition, method of making, and method of use thereof
BR0311266A (pt) 2002-05-24 2005-02-22 Bayer Cropscience Ag Processo para a preparação de derivados de tioalquilamina
CN1960973A (zh) * 2004-03-30 2007-05-09 惠氏公司 作为去甲肾上腺素(ne)与血清素(5－h t)活性和单胺重摄取的调控剂以治疗血管舒缩症状(vms)的1－(1h－吲哚－1－基)－3－(4－甲基哌嗪－1－基)－1－苯基丙烷－2－醇衍生物和相关化合物
US7517899B2 (en) 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
EP2078712B1 (en) 2004-05-03 2015-06-10 Janssen Pharmaceutica N.V. Indole derivatives as selective androgen receptor modulators (sarms)
US7282507B2 (en) 2004-05-03 2007-10-16 Janssen Pharmaceutica N.V. Indole derivatives as selective androgen receptor modulators (SARMS)
US7427682B2 (en) 2004-05-03 2008-09-23 Janssen Pharmaceutica N.V. Indole derivatives as selective androgen receptor modulators (SARMS)
AU2005250116B2 (en) * 2004-06-01 2011-01-20 F. Hoffmann-La Roche Ag 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitor
ES2377771T3 (es) * 2005-07-29 2012-03-30 Pfizer Products Inc. Derivados de pirrolo [2,3-d]pirimidina, sus intermedios y síntesis
GB0526246D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
CN101426778A (zh) * 2006-03-15 2009-05-06 惠氏公司 作为组胺-3拮抗剂的n-经取代-氮杂环基胺
MX2008011791A (es) * 2006-03-15 2008-09-25 Wyeth Corp Azaciclilaminas-n-sustituidas como antagonistas de histamina-3.
WO2008042571A2 (en) * 2006-09-29 2008-04-10 Smithkline Beecham Corporation Substituted indole compounds
KR101335843B1 (ko) * 2008-08-20 2013-12-02 조에티스 엘엘씨 피롤로[2,3-ｄ]피리미딘 화합물
WO2010118287A1 (en) 2009-04-10 2010-10-14 Radius Health, Inc. Selective androgen receptor modulators
CN102574860A (zh) * 2009-10-15 2012-07-11 辉瑞大药厂 吡咯并[2,3-d]嘧啶化合物
EP2513114B1 (en) * 2009-12-18 2014-04-02 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine compounds
EP2590647B1 (en) 2010-07-07 2017-11-08 Board of Regents of the University of Texas System Pro-neurogenic compounds
MX351305B (es) * 2011-01-20 2017-10-09 Merck Sharp & Dohme Antagonistas del receptor de mineralocorticoides.
SI2796460T1 (sl) * 2011-12-21 2018-10-30 Jiangsu Hengrui Medicine Co. Ltd Pirolni šestčlenski derivat heteroarilnega obroča, postopek priprave zanj in medicinske uporabe le-tega
BR112015000940B1 (pt) * 2012-07-17 2022-05-17 Glaxosmithkline Intellectual Property (No. 2) Limited Composto, composição farmacêutica, e, uso de um composto
EP3097077A1 (en) * 2014-01-21 2016-11-30 Glaxosmithkline Intellectual Property (No. 2) Limited Crystalline forms of (r)-1 -(1-(methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)indoline-5-carbonitrile

Also Published As

Publication number Publication date
US9533948B2 (en) 2017-01-03
KR20150032333A (ko) 2015-03-25
CN104619693B (zh) 2019-08-13
KR102127939B1 (ko) 2020-06-29
US10710963B2 (en) 2020-07-14
IL236448A0 (en) 2015-02-26
MX2015000825A (es) 2015-07-17
HUE036238T2 (hu) 2018-06-28
PT2875013T (pt) 2018-02-28
SG11201408493WA (en) 2015-02-27
US20150080449A1 (en) 2015-03-19
MY173845A (en) 2020-02-24
LT2875013T (lt) 2018-02-26
US20170073309A1 (en) 2017-03-16
AU2013291721A1 (en) 2015-02-26
MX349943B (es) 2017-08-21
BR112015000940A2 (pt) 2017-06-27
ZA201500096B (en) 2017-07-26
HRP20180061T1 (hr) 2018-02-23
BR112015000940B1 (pt) 2022-05-17
EP2875013B1 (en) 2017-11-29
HK1208867A1 (en) 2016-03-18
PH12015500104B1 (en) 2015-03-02
DOP2015000004A (es) 2015-03-15
US11299457B2 (en) 2022-04-12
WO2014013309A1 (en) 2014-01-23
RS56810B1 (sr) 2018-04-30
EA026371B1 (ru) 2017-03-31
JO3384B1 (ar) 2019-03-13
DK2875013T3 (en) 2018-01-22
PL2875013T3 (pl) 2018-06-29
SI2875013T1 (en) 2018-03-30
CL2015000119A1 (es) 2015-04-24
US20200270210A1 (en) 2020-08-27
CR20150008A (es) 2015-03-09
CY1120064T1 (el) 2018-12-12
CA2879104C (en) 2020-08-25
ME02996B (me) 2018-10-20
JP6106746B2 (ja) 2017-04-05
TWI574946B (zh) 2017-03-21
ES2657912T3 (es) 2018-03-07
US8957104B2 (en) 2015-02-17
AU2013291721B2 (en) 2016-02-25
SMT201800115T1 (it) 2018-03-08
AR091770A1 (es) 2015-02-25
US10196353B2 (en) 2019-02-05
PH12015500104A1 (en) 2015-03-02
NZ703129A (en) 2017-06-30
TW201416349A (zh) 2014-05-01
EA026371B8 (ru) 2017-06-30
IN2014KN02993A (cg-RX-API-DMAC7.html) 2015-05-08
MY198512A (en) 2023-09-01
EP2875013A1 (en) 2015-05-27
PE20150371A1 (es) 2015-03-27
EA201492237A1 (ru) 2015-06-30
CO7240378A2 (es) 2015-04-17
JP2015522603A (ja) 2015-08-06
IL236448A (en) 2016-10-31
US20140024694A1 (en) 2014-01-23
US20190127326A1 (en) 2019-05-02
CA2879104A1 (en) 2014-01-23
CN104619693A (zh) 2015-05-13

Similar Documents

Publication Publication Date Title
UY34911A (es) Compuestos no esteroideos moduladores del receptor de andrógeno.
CO7151530A2 (es) Anticuerpos e inmunoconjugados anti-cd79b
EA201891209A1 (ru) Модуляторы хемокиновых рецепторов
EA201791310A1 (ru) Химерные антигенные рецепторы к bcma
ES2529890T8 (es) Agentes para el tratamiento de trastornos que implican la modulación de los receptores rianodina
UA109931C2 (xx) Піримідинциклогексильні модулятори глюкокортикоїдних рецепторів
CR20140479A (es) Moduladores del receptor del estrogeno y sus usos
CL2016001871A1 (es) Anticuerpos humanos para pd-1
CL2018000883A1 (es) Moduladores del receptor x farnesoide
CO7111273A2 (es) Anticuerpos cd47 y métodos de uso de los mismos
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
CL2015001733A1 (es) Compuestos derivados de lactamas fusionadas de arilo y heteroarilo, moduladores de ezh2; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento del cancer.
CO7151485A2 (es) Anticuerpos anti-sez6 y métodos de empleo
CO7160047A2 (es) Compuestos y composiciones que modulan la actividad del receptor del factor de crecimiento epidérmico (egfr)
GT201300196A (es) Moduladores del receptor de glucagón
DK3490986T3 (da) Piperidin-cxcr7-receptormodulatorer
DK3625228T3 (da) Pyrimidinderivater som pge2-receptormodulatorer
DK3294713T5 (da) Substituerede tetrahydroquinolinonforbindelser som ror-gamma-modulatorer
ES2930298T3 (es) Moduladores del receptor de glucocorticoides de azadecalina condensada con heteroaril-cetona
CL2017003147A1 (es) Moduladores de receptor nuclear
CR20140440A (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina
DK3625222T3 (da) Phenylderivater som pge2-receptormodulatorer
GT201400067A (es) Moduladores selectivos del receptor androgeno
DK3145916T3 (da) Imidazolderivater som formylpeptidreceptormodulatorer
CL2016003209A1 (es) Empalme para su uso con cable blindado

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20220104